newsFirst drug for acute graft-versus-host disease prevention approved by FDA22 December 2021 | By Hannah Balfour (European Pharmaceutical Review)BMS’s Orencia (abatacept) has been approved by the US FDA for prophylaxis of acute graft-versus-host disease (aGvHD) in patients aged two years plus.
newsNICE recommends 7 DMARDs for severe rheumatoid arthritis26 January 2016 | By Victoria WhiteNICE recommends the seven biological disease modifying drugs as options for treating severe rheumatoid arthritis which has not responded to intensive therapy with a combination of conventional DMARDs...